The results of a study in healthy volunteers presented by Dr. Anna Becker suggest that SSRIs should not be discontinued prior to psilocybin treatment.
In a British general hospital, not a single patient tested positive for influenza nor respiratory syncytial virus (RSV) during the peak flu season in January 2021.
As COVID measures relaxed, pollution increased. Oxidative stress and systematic inflammation in healthy individuals was observed.
The digital HERB system proved successful in early-stage hypertension patients, which could lower their blood pressure and adopt positive lifestyle interventions.
The STEP trial revealed that lowering systolic blood pressure below 130 mmHg in +60 year-old patients led to a 26% reduction of adverse cardiovascular events.
Dr. Anna Ciaunica gave an insight into her work at the INSIGHT 2021 Conference and explained how the COVID-19 crisis-induced lack of tactile experience favours a depersonalitation disorder.
Psychedelic therapy and psychotherapy - differences and similarities and potential problems for therapists. Prof. Matthew Johnson (Johns Hopkins University) shared his work at the INSIGHT 2021 Conference.
Psychedelics could represent a new treatment approach in psychiatry. But can they combat the global health crisis? At the INSIGHT 2021 Conference, Prof. Dr. Gerhard Gründer takes a critical look on the issue.
For neuroscientist Dr. Martha Havenith, psychedelics are not the only way to explore altered states of consciousness. She works with voluntary hyperventilation (Breathwork) to achieve different perceptions.
Assigning all survivors of an out-of-hospital cardiac arrest (OHCA) to an early coronary angiogram turned out to have no positive influence on the 30-day all-cause mortality.
Thromboprophylaxis with a heparin therapeutic dose greatly reduced major thromboembolic events in COVID-19 hospitalisations compared with standard therapy.
In parts of public discourse and scientific literature, psychedelic therapies are claimed to transform and revolutionise psychiatry and mental healthcare. Can psychedelics live up to this claim?
The MICHELLE trial found rivaroxaban thrombo-prophylaxis beneficial for COVID-19 patients. Some individuals had a 67% risk reduction in clinical outcome composites.
Amidst anti-vaccine passport demonstrators, a masked Dr. Haegy stands alone, with a handmade sign reminding us of some figures: 2,000 intensive care patients, of which 85% were not vaccinated.
Months after infection with SARS-CoV-2, some people are still battling fatigue. In a study, severe fatigue was negatively correlated with disease severity up to 10 months after initial infection.
Intensive livestock has been associated with health risks. Residential exposure to its emitted endotoxin was linked to increased species richness in COPD.
A meta-analysis of three large primary prevention trials showed fixed-dose combination treatments help prevent CV death, MI, stroke, or revascularisation.
The FIGARO-DKD trial investigated mineralocorticoid receptor antagonist treatment effects on cardiovascular outcomes in patients with mild-to-moderate kidney disease and T2D.
IMT consists of breathing exercises. It is a home-based rehabilitation tool that contributes significantly to COVID-19 recovery with only 3 sessions per week.
The DECIDE-Salt trial assessed dietary sodium-reduction strategies over 2 years in residential care patients, targeting significant reductions in systolic blood pressure.